Accompanying slides, A4 KOL Series: Episode 2, Dr April Armstrong

ASLAN A4 Series:

Aspects of Atopic Dermatitis and ASLAN004

with Dr April Armstrong

20 January 2022

NASDAQ: ASLN

1

Aspects of Atopic Dermatitis and ASLAN004

•	Company introduction and ASLAN004	Dr Carl Firth
• A closer look: Key factors affecting
	responses in Atopic Dermatitis clinical trials	Dr April Armstrong
•	ASLAN004 Phase 2b trial design	Dr Karen Veverka
•	Fireside Chat	Dr Armstrong & Dr Veverka
•	Q&A
•	Close

2

Introduction

Dr Carl Firth

CEO

3

Legal disclaimer

This presentation contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the

Company's business strategy, the Company's plans to develop and commercialize its product candidates, the safety and efficacy of the Company's product candidates, including their potential to be best-in-class, the Company's plans and expected timing with respect to clinical trials, clinical trial enrollment and clinical trial results for its product candidates, the Company's plans and expected timing with respect to regulatory filings and approvals, the size and growth potential of the markets for the Company's product candidates, and the potential for ASLAN004 as a first-in-class treatment for atopic dermatitis. The Company's estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial

performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation the risk factors described in the Company's US Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company's Form 20-F filed with the U.S. Securities and Exchange Commission (the "SEC") on April 23, 2021.

This presentation discusses product candidates that are under clinical study and which have not yet been approved for marketing by the US Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied. Caution should be exercised when comparing data across trials of different products and product candidates. Differences existing between trial designs and patient populations and characteristics. The results across such trials may not have interpretative value on our existing or future results.

All statements other than statements of historical fact are forward-looking statements. The words "believe," "view," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan," or the negative of those terms, and similar expressions that convey uncertainty

of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.

4

ASLAN Pharmaceuticals

• Clinical-stage,immunology-focused biopharma developing innovative therapies to treat inflammatory disease

• ASLAN004, also known as eblasakimab, is a potential first-in-class antibody targeting the IL-13 receptor that has the potential to improve upon current biologics used to treat allergic disease
• • There are few safe and effective treatments for moderate-to-severe atopic dermatitis (AD), expected to be a $24B market by 20291. Despite dupilumab advancing the standard of care, physicians / patients still seek additional options.
  • Topline data from recently completed multiple ascending dose study conclusively establishes proof of concept for ASLAN004 in AD, and supports a potentially differentiated safety and efficacy profile
  • Preparations for Phase 2b underway, evaluating 2-weekly and 4-weekly regimens. FPI expected Jan 2022
• ASLAN003 is a second generation DHODH inhibitor with the potential to be best-in-classfor autoimmune disease
• • Stronger in vitro potency and lower potential for hepatotoxicity compared to other DHODH inhibitors
  • Expecting to initiate phase 2 in IBD in 1H 2022. Planning future studies in autoimmune skin diseases

• Strong cash position ($100M2) with runway to late 2023

1	Decision Resources Group, June 2021	5
2	As of Q3 ending September 30, 2021